Propanc Biopharma, Inc.

PPCB · NASDAQ
Analyze with AI
6/30/2025
6/30/2024
6/30/2023
6/30/2022
Assets
Cash & Equivalents$12$21$10$4
Short-Term Investments$0$0$0$0
Receivables$5$3$3$2
Inventory$0$0$0$0
Other Curr. Assets$8,335$1$6$9
Total Curr. Assets$8,353$25$19$15
Property Plant & Equip (Net)$59$18$39$65
Goodwill$0$0$0$0
Intangibles$0$0$0$0
Long-Term Investments$0$0$0$0
Tax Assets$0$0$0$0
Other NC Assets$11,220$29$2$2
Total NC Assets$11,279$47$41$67
Other Assets$0$0$0$0
Total Assets$19,632$72$60$82
Liabilities
Payables$1,250$1,213$967$943
Short-Term Debt$1,580$890$527$998
Tax Payable$0$0$0$0
Deferred Revenue$0$0$0$0
Other Curr. Liab.$2,749$1,690$1,665$1,122
Total Curr. Liab.$5,578$3,793$3,158$3,063
LT Debt$147$59$19$42
Deferred Rev, NC$0$0$0$0
Deferred Tax Liab, NC$0$0$0$0
Other NC Liab.$0$0$0$0
Total NC Liab.$147$59$19$42
Other Liabilities$0$0$0$0
Cap. Leases$59$19$41$63
Total Liabilities$5,726$3,851$3,178$3,105
Equity
Pref Stock$0$0$0$5
Common Stock$12$479$8$0
Retained Earnings-$125,622-$66,698-$64,685-$61,558
AOCI$1,319$1,270$1,295$1,235
Other Equity$138,197$61,171$60,265$57,294
Total Equity$13,906-$3,779-$3,117-$3,024
Supplemental Information
Minority Interest$0$0$0$0
Total Liab. & Tot. Equity$19,632$72$60$82
Net Debt$1,715$927$536$1,036